Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Receives Average Recommendation of “Buy” from Analysts

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has received an average recommendation of “Buy” from the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $24.64.

A number of equities research analysts have recently commented on AMPH shares. BidaskClub raised Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research report on Wednesday, July 10th. TheStreet raised Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Wednesday, August 7th. Finally, Wells Fargo & Co set a $29.00 price target on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, June 6th.

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,942 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $21.00, for a total transaction of $103,782.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Yakob Liawatidewi sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $20.73, for a total value of $103,650.00. Following the transaction, the senior vice president now directly owns 47,188 shares in the company, valued at approximately $978,207.24. The disclosure for this sale can be found here. Insiders have sold a total of 26,557 shares of company stock worth $549,583 in the last ninety days. Insiders own 30.80% of the company’s stock.

Large investors have recently bought and sold shares of the business. Martingale Asset Management L P increased its position in shares of Amphastar Pharmaceuticals by 8.2% during the 1st quarter. Martingale Asset Management L P now owns 220,438 shares of the company’s stock worth $4,505,000 after purchasing an additional 16,692 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in shares of Amphastar Pharmaceuticals by 52,407.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,351 shares of the company’s stock worth $150,000 after acquiring an additional 7,337 shares during the period. Sawtooth Solutions LLC bought a new position in shares of Amphastar Pharmaceuticals during the 1st quarter worth approximately $215,000. Two Sigma Advisers LP bought a new position in shares of Amphastar Pharmaceuticals during the 4th quarter worth approximately $275,000. Finally, Nordea Investment Management AB boosted its stake in shares of Amphastar Pharmaceuticals by 1.7% during the 1st quarter. Nordea Investment Management AB now owns 254,071 shares of the company’s stock worth $5,192,000 after acquiring an additional 4,343 shares during the period. 47.61% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ AMPH traded up $0.48 during mid-day trading on Friday, reaching $21.38. 294,600 shares of the company’s stock were exchanged, compared to its average volume of 183,615. The firm has a market capitalization of $987.03 million, a price-to-earnings ratio of 101.81 and a beta of 1.35. The company has a current ratio of 2.81, a quick ratio of 1.83 and a debt-to-equity ratio of 0.13. The business has a fifty day simple moving average of $20.26 and a 200 day simple moving average of $21.31. Amphastar Pharmaceuticals has a twelve month low of $17.71 and a twelve month high of $25.43.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.08 EPS for the quarter, topping the Zacks’ consensus estimate of $0.03 by $0.05. The company had revenue of $79.00 million for the quarter, compared to analyst estimates of $78.90 million. Amphastar Pharmaceuticals had a return on equity of 5.52% and a net margin of 16.33%. Amphastar Pharmaceuticals’s revenue was up 11.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.03 earnings per share. Equities research analysts predict that Amphastar Pharmaceuticals will post 0.15 earnings per share for the current fiscal year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Featured Article: The risks of owning bonds

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.